[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.241.199. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
February 23, 2011

Direct-to-Consumer Advertising With Interactive Internet MediaGlobal Regulation and Public Health Issues

Author Affiliations

Author Affiliations: Institute of Health Law Studies, California Western School of Law (Dr Liang and Mr Mackey), Department of Anesthesiology and San Diego Center for Patient Safety, University of California, San Diego School of Medicine (Dr Liang), San Diego State University–University of California, San Diego Joint Program on Global Health (Mr Mackey).

JAMA. 2011;305(8):824-825. doi:10.1001/jama.2011.203

Direct-to-consumer advertising (DTCA) is legal only in the United States and New Zealand and has been linked with drug overutilization, public health concerns, and higher costs.1 Despite global proscriptions, DTCA is the most rapidly increasing form of pharmaceutical marketing, with approximately $4 billion in US expenditures, outpacing physician marketing and research and development.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×